

March 2022

Gan & Lee Pharmaceuticals USA Corp.  
520 US Hwy 22 East, Suite 302  
Bridgewater, NJ 08807

Dear EudraCT:

This is the update and the reason for the **Study GL-LSPT1-3003**:

Gan & Lee did not move forward with the Phase 3 (GL-LSPT1-3003) study because of an update to the guidance on biosimilar insulins from the regulatory authorities.

Thank You,

Jia Lu (Luke)

Executive Director of Global Clinical Development  
Jia.Lu@ganlee.us